Atsuhito Uneda
YOU?
Author Swipe
View article: TMET-25. TNFR1 Knockdown Sensitizes Glioblastoma Cells to Cell Death
TMET-25. TNFR1 Knockdown Sensitizes Glioblastoma Cells to Cell Death Open
BACKGROUND Glioblastoma (GBM) is the brain tumor with poor prognosis, despite advances in surgery, radiation, and chemotherapy. Tumor necrosis factor (TNF) signaling, particularly through TNF receptor 1 (TNFR1), has been associated with in…
View article: Dual molecular therapy targeting tumor cell heterogeneity improves therapeutic efficacy in glioblastoma
Dual molecular therapy targeting tumor cell heterogeneity improves therapeutic efficacy in glioblastoma Open
View article: Changes in adrenoceptor expression level contribute to the cellular plasticity of glioblastoma cells
Changes in adrenoceptor expression level contribute to the cellular plasticity of glioblastoma cells Open
Glioblastoma cells are known to regulate their cellular plasticity in response to their surrounding microenvironment, but it is not fully understood what factors contribute to the cells' changing plasticity. Here, we found that glioblastom…
View article: New Anti‐Angiogenic Therapy for Glioblastoma With the Anti‐Depressant Sertraline
New Anti‐Angiogenic Therapy for Glioblastoma With the Anti‐Depressant Sertraline Open
Background and Aims Anti‐angiogenic therapies prolong patient survival in some malignancies but not glioblastoma. We focused on the relationship between the differentiation of glioma stem like cells (GSCs) into tumor derived endothelial ce…
View article: 10038-ANGI-2 NEW ANTI-ANGIOGENIC THERAPY WITH THE ANTI-DEPRESSANT TOWARD TUMOR DERIVED ENDOTHELIAL CELLS (TDECS)
10038-ANGI-2 NEW ANTI-ANGIOGENIC THERAPY WITH THE ANTI-DEPRESSANT TOWARD TUMOR DERIVED ENDOTHELIAL CELLS (TDECS) Open
BACKGROUND Anti-angiogenic therapy has been reported to prolong patient survival in some malignancies, but has not been shown to be effective in glioblastoma. We focused on the relationship between the differentiation of glioma stem-like c…
View article: Development of a rapid and comprehensive genomic profiling test supporting diagnosis and research for brain tumors
Development of a rapid and comprehensive genomic profiling test supporting diagnosis and research for brain tumors Open
A prompt and reliable molecular diagnosis for brain tumors has become crucial in precision medicine. While Comprehensive Genomic Profiling (CGP) has become feasible, there remains room for enhancement in brain tumor diagnosis due to the pa…
View article: Supplementary Figure 3 from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion
Supplementary Figure 3 from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion Open
Bevacizumab treatment led to increase in invasive and high expression of Î'-catenin. Silencing of Î'-catenin decreased bevacizumab-induced glioma invasion and Î'-catenin expression. Overexpressed Î'-catenin tumor cells showed more invasive…
View article: Supplementary Figure 4 from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion
Supplementary Figure 4 from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion Open
WST-1 assay and two-chamber assay
View article: Supplementary Figure 2 from Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways
Supplementary Figure 2 from Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways Open
Supplementary Figure 2 shows In vitro scratch migration assay.
View article: Supplementary Figure 1 from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion
Supplementary Figure 1 from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion Open
Glioma cell cytotoxicity with bevacizumab treatment in vitro
View article: Supplementary Figure 2 from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion
Supplementary Figure 2 from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion Open
Bevacizumab increased the rate of wound closure
View article: Supplementary Figure 2 from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion
Supplementary Figure 2 from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion Open
Bevacizumab increased the rate of wound closure
View article: Data from Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways
Data from Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways Open
Anti-VEGF treatments such as bevacizumab have demonstrated convincing therapeutic advantage in patients with glioblastoma. However, bevacizumab has also been reported to induce invasiveness of glioma. In this study, we examined the effects…
View article: Supplementary Figure 1 from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion
Supplementary Figure 1 from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion Open
Glioma cell cytotoxicity with bevacizumab treatment in vitro
View article: Supplementary Figure 1 from Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways
Supplementary Figure 1 from Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways Open
Supplementary Figure 1 shows Evaluation of glioma cells infected by oncolytic virus and conditioned medium.
View article: Data from Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways
Data from Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways Open
Anti-VEGF treatments such as bevacizumab have demonstrated convincing therapeutic advantage in patients with glioblastoma. However, bevacizumab has also been reported to induce invasiveness of glioma. In this study, we examined the effects…
View article: Supplementary Figure 4 from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion
Supplementary Figure 4 from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion Open
WST-1 assay and two-chamber assay
View article: Data from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion
Data from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion Open
The combination of bevacizumab with temozolomide and radiotherapy was shown to prolong progression-free survival in newly diagnosed patients with glioblastoma, and this emphasizes the potential of bevacizumab as a glioma treatment. However…
View article: Data from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion
Data from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion Open
The combination of bevacizumab with temozolomide and radiotherapy was shown to prolong progression-free survival in newly diagnosed patients with glioblastoma, and this emphasizes the potential of bevacizumab as a glioma treatment. However…
View article: Supplementary Figure 3 from Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways
Supplementary Figure 3 from Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways Open
Supplementary Figure 3 shows Full scans of the western blotting shown in the figure 6.
View article: Supplementary Figure 1 from Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways
Supplementary Figure 1 from Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways Open
Supplementary Figure 1 shows Evaluation of glioma cells infected by oncolytic virus and conditioned medium.
View article: Supplementary Figure 2 from Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways
Supplementary Figure 2 from Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways Open
Supplementary Figure 2 shows In vitro scratch migration assay.
View article: Supplementary Figure 3 from Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways
Supplementary Figure 3 from Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways Open
Supplementary Figure 3 shows Full scans of the western blotting shown in the figure 6.
View article: Supplementary Figure 3 from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion
Supplementary Figure 3 from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion Open
Bevacizumab treatment led to increase in invasive and high expression of Î'-catenin. Silencing of Î'-catenin decreased bevacizumab-induced glioma invasion and Î'-catenin expression. Overexpressed Î'-catenin tumor cells showed more invasive…
View article: IDH-mutant Astrocytoma Arising in the Brainstem with Symptom Improvement by Foramen Magnum Decompression: A Case Report
IDH-mutant Astrocytoma Arising in the Brainstem with Symptom Improvement by Foramen Magnum Decompression: A Case Report Open
Diffusely infiltrative midline gliomas are known to have a poor prognosis. The standard treatment for typical diffuse midline glioma in the pons is local radiotherapy as surgical resection is inappropriate. This case reports a brainstem gl…
View article: Recent advances in the molecular understanding of medulloblastoma
Recent advances in the molecular understanding of medulloblastoma Open
Medulloblastoma is the most common pediatric malignant brain tumor composed of four molecular subgroups. Recent intensive genomics has greatly contributed to our understanding of medulloblastoma pathogenesis. Sequencing studies identified …
View article: GEN-8 COMPREHENSIVE WHOLE GENOME SEQUENCING ANALYSIS ELUCIDATES STRUCTURAL VARIANTS IN MEDULLOBLASTOMA
GEN-8 COMPREHENSIVE WHOLE GENOME SEQUENCING ANALYSIS ELUCIDATES STRUCTURAL VARIANTS IN MEDULLOBLASTOMA Open
Introduction Medulloblastoma is the most common malignant pediatric brain tumor with a poor prognosis. International collaborative efforts for sequencing the genomes of medulloblastomas have delineated the landscape of coding mutations. Ho…
View article: GEN-9 WHOLE GENOME SEQUENCING ANALYSIS REVEALS STRUCTURAL VARIANTS CONTRIBUTE TO TUMOR EVOLUTION IN IDH-MUTANT GLIOMA
GEN-9 WHOLE GENOME SEQUENCING ANALYSIS REVEALS STRUCTURAL VARIANTS CONTRIBUTE TO TUMOR EVOLUTION IN IDH-MUTANT GLIOMA Open
Introduction Recent large-scale sequencing projects for IDH-mutant adult-type diffuse glioma (Astrocytoma, IDH-mutant and Oligodendroglioma, IDH-mutant and 1p/19q-codeleted) have revealed the genetic landscape of coding mutations. However,…
View article: COT-8 DEVELOPMENT OF TARGETED GENE PANEL FOR RAPID MOLECULAR DIAGNOSIS OF BRAIN TUMORS
COT-8 DEVELOPMENT OF TARGETED GENE PANEL FOR RAPID MOLECULAR DIAGNOSIS OF BRAIN TUMORS Open
Background Brain tumors are diagnosed based on pathological and genetic features defined by WHO classification. Although targeted gene panels are clinically available, most of them do not cover all the necessary genes for the diagnosis of …
View article: GEN-10 WHOLE GENOME LANDSCAPE OF GLIOBLASTOMA, IDH-WILD TYPE
GEN-10 WHOLE GENOME LANDSCAPE OF GLIOBLASTOMA, IDH-WILD TYPE Open
Introduction: Glioblastoma, IDH-wild type (GBM) is the most common malignant brain tumor with a dismal prognosis. Although its coding region is well-analyzed, little is yet known about the landscape of whole-genome in GBM. Here, we analyze…